...
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Molecular epidemiology of malaria in Cameroon. XIV. Plasmodium falciparum chloroquine resistance transporter (PFCRT) gene sequences of isolates before and after chloroquine treatment.
【24h】

Molecular epidemiology of malaria in Cameroon. XIV. Plasmodium falciparum chloroquine resistance transporter (PFCRT) gene sequences of isolates before and after chloroquine treatment.

机译:喀麦隆疟疾的分子流行病学。十四。疟原虫恶性疟原虫氯喹抗性转运蛋白(PFCRT)基因序列在氯喹处理之前和之后。

获取原文
获取原文并翻译 | 示例
           

摘要

Laboratory studies have strongly suggested that the gene coding for Plasmodium falciparum chloroquine resistance transporter (PFCRT) may play a determinant role in chloroquine resistance. A clinical study in Mali also found evidence for selection of the key PFCRT amino acid substitution, Lys76Thr, in patients who fail to respond to chloroquine treatment. To test the hypothesis that in vivo selection of mutant PFCRT alleles occurs after chloroquine treatment, PFCRT and merozoite surface antigen 2 (msa-2) polymorphisms were compared between 61 pretreatment and posttreatment paired samples from children with either clinical or parasitologic failure. There were six wild-type PFCRT alleles, 44 mutant alleles, and 11 mixed alleles among pretreatment isolates. All posttreatment parasites had mutant PFCRT alleles. Recrudescence accounted for 42 of 61 posttreatment infections, while 19 posttreatment infections were due to new infection (including all isolates with Lys-76 before treatment and Thr-76 after treatment). Seven pretreatment isolates with mixed PFCRT alleles had only Thr-76 on recrudescence, providing a direct evidence for in vivo selection for mutant PFCRT. Although the presence of mutant PFCRT alleles in pretreatment isolates is not predictive of chloroquine treatment failure, our data support the hypothesis that in vivo selection for recrudescent parasites carrying mutant PFCRT alleles occurs. These results may have important implications for the future surveillance of chloroquine resistance by the use of molecular markers.
机译:实验室研究强烈建议,编码恶性疟原虫氯喹抗性转运蛋白(PFCRT)的基因可能在氯喹抗性中起决定性作用。在马里进行的一项临床研究还发现,对氯喹治疗无效的患者可以选择关键的PFCRT氨基酸取代Lys76Thr。为了验证在氯喹治疗后体内选择突变型PFCRT等位基因的假设,我们比较了61例临床或寄生虫失败儿童的治疗前和治疗后配对样本中的PFCRT和裂殖子表面抗原2(msa-2)多态性。预处理分离物中有6个野生型PFCRT等位基因,44个突变等位基因和11个混合等位基因。所有后处理寄生虫均具有突变的PFCRT等位基因。复发占61个治疗后感染中的42个,而19个治疗后感染是由于新感染(包括所有在治疗前具有Lys-76和在治疗后具有Thr-76的分离株)。七个带有混合PFCRT等位基因的预处理菌株在复发时只有Thr-76,这为体内选择突变PFCRT提供了直接证据。尽管在预处理分离株中突变型PFCRT等位基因的存在不能预示氯喹治疗失败,但我们的数据支持以下假设,即在体内选择携带突变型PFCRT等位基因的复发性寄生虫。这些结果可能对未来使用分子标记物监测氯喹耐药性具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号